{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:51:16Z","timestamp":1740135076515,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Key Research Project of Beijing Natural Science Foundation","award":["No. Z220013"],"award-info":[{"award-number":["No. Z220013"]}]},{"name":"the National High Level Hospital Clinical Research Funding","award":["No. 2022-PUMCH-A-117, 2022-PUMCH-B-083, 2022-PUMCH-C-010, 2022-PUMCH-C-022 and 2022-PUMCH-D-003"],"award-info":[{"award-number":["No. 2022-PUMCH-A-117, 2022-PUMCH-B-083, 2022-PUMCH-C-010, 2022-PUMCH-C-022 and 2022-PUMCH-D-003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-13296-1","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T15:36:34Z","timestamp":1734536194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of long-acting versus short-acting granulocyte colony stimulating factor after radiotherapy in gynecologic malignancies: a prospective observational cohort study"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0972-9976","authenticated-orcid":false,"given":"Xiaojing","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8601-7510","authenticated-orcid":false,"given":"Ming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2541-0025","authenticated-orcid":false,"given":"Shuiqing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7421-8251","authenticated-orcid":false,"given":"Xianjie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4387-8457","authenticated-orcid":false,"given":"Sen","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8723-3461","authenticated-orcid":false,"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"13296_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1159\/000345626","volume":"58","author":"BB Yang","year":"2012","unstructured":"Yang BB, et al. Prevention of chemotherapy-induced neutropenia with pegfilgrastim: pharmacokinetics and patient outcomes. Chemotherapy. 2012;58:387\u201398.","journal-title":"Chemotherapy"},{"key":"13296_CR2","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","volume":"23","author":"CL Vogel","year":"2005","unstructured":"Vogel CL, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23:1178\u201384.","journal-title":"J Clin Oncol"},{"key":"13296_CR3","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1200\/JCO.2003.03.040","volume":"21","author":"JM Vose","year":"2003","unstructured":"Vose JM, et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol. 2003;21:514\u20139.","journal-title":"J Clin Oncol"},{"key":"13296_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/annonc\/mdg019","volume":"14","author":"MD Green","year":"2003","unstructured":"Green MD, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14:29\u201335.","journal-title":"Ann Oncol"},{"key":"13296_CR5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1200\/JCO.2002.20.3.727","volume":"20","author":"FA Holmes","year":"2002","unstructured":"Holmes FA, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer. J Clin Oncol. 2002;20:727\u201331.","journal-title":"J Clin Oncol"},{"key":"13296_CR6","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1007\/s00520-015-2686-9","volume":"23","author":"L Wang","year":"2015","unstructured":"Wang L, et al. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer. 2015;23:3131\u201340.","journal-title":"Support Care Cancer"},{"key":"13296_CR7","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1177\/1078155215625459","volume":"22","author":"S Mitchell","year":"2016","unstructured":"Mitchell S, et al. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: a systematic review. J Oncol Pharm Pract. 2016;22:702\u201316.","journal-title":"J Oncol Pharm Pract"},{"key":"13296_CR8","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00520-014-2457-z","volume":"23","author":"AM Pfeil","year":"2015","unstructured":"Pfeil AM, et al. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Support Care Cancer. 2015;23:525\u201345.","journal-title":"Support Care Cancer"},{"key":"13296_CR9","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1007\/s12325-018-0798-6","volume":"35","author":"P Cornes","year":"2018","unstructured":"Cornes P, et al. Systematic review and Meta-analysis of short- versus long-acting granulocyte colony-stimulating factors for reduction of Chemotherapy-Induced Febrile Neutropenia. Adv Ther. 2018;35:1816\u201329.","journal-title":"Adv Ther"},{"key":"13296_CR10","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, et al. Management of febrile neutropaenia: ESMO Clinical Practice guidelines. Ann Oncol. 2016;27:v111\u20138.","journal-title":"Ann Oncol"},{"key":"13296_CR11","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae) [J]. 2017."},{"key":"13296_CR12","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, et al. Recommendations for the Use of WBC Growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33:3199\u2013212.","journal-title":"J Clin Oncol"},{"key":"13296_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8\u201332.","journal-title":"Eur J Cancer"},{"key":"13296_CR14","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/sj.bjc.6602076","volume":"91","author":"H Tsuda","year":"2004","unstructured":"Tsuda H, et al. Phase I-II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer. Br J Cancer. 2004;91:1032\u20137.","journal-title":"Br J Cancer"},{"key":"13296_CR15","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ejogrb.2006.04.005","volume":"131","author":"G Ferrandina","year":"2007","unstructured":"Ferrandina G, et al. Carboplatin-based neoadjuvant treatment with peripheral blood stem cell and growth factor support in locally advanced cervical cancer patients with bulky metastatic lymph nodes. Eur J Obstet Gynecol Reprod Biol. 2007;131:236\u20138.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"13296_CR16","first-page":"373","volume":"9","author":"L Li","year":"2019","unstructured":"Li L, et al. The prophylactic effects of long-acting granulocyte colony-stimulating factor for febrile neutropenia in newly diagnosed patients with epithelial ovarian cancer: a randomised controlled study. BMJ Support Palliat Care. 2019;9:373\u201380.","journal-title":"BMJ Support Palliat Care"},{"key":"13296_CR17","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1634\/theoncologist.12-12-1416","volume":"12","author":"L Balducci","year":"2007","unstructured":"Balducci L, et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist. 2007;12:1416\u201324.","journal-title":"Oncologist"},{"key":"13296_CR18","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1007\/s00520-017-3842-1","volume":"25","author":"M Aapro","year":"2017","unstructured":"Aapro M, et al. Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Support Care Cancer. 2017;25:3295\u2013304.","journal-title":"Support Care Cancer"},{"key":"13296_CR19","unstructured":"Cancer N I O. Common Terminology Criteria for Adverse Events (CTCAE) v4.0 [J]. 2009."},{"key":"13296_CR20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s13014-015-0495-4","volume":"10","author":"L Li","year":"2015","unstructured":"Li L, et al. Postoperative external beam irradiation with and without brachytherapy in pelvic node-positive IB1-IIA2 cervical cancer patients: a retrospective clinical study. Radiat Oncol. 2015;10:189.","journal-title":"Radiat Oncol"},{"key":"13296_CR21","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1159\/000348383","volume":"84","author":"H Iwase","year":"2013","unstructured":"Iwase H, et al. Concurrent chemoradiotherapy with a novel fluoropyrimidine, S-1, and cisplatin for locally advanced esophageal cancer: long-term results of a phase II trial. Oncology. 2013;84:342\u20139.","journal-title":"Oncology"},{"key":"13296_CR22","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/IGC.0000000000000380","volume":"25","author":"C Kunos","year":"2015","unstructured":"Kunos C, et al. A phase I-II evaluation of Veliparib (NSC #737664), Topotecan, and Filgrastim or Pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology\/Gynecologic Oncology Group Study. Int J Gynecol Cancer. 2015;25:484\u201392.","journal-title":"Int J Gynecol Cancer"},{"key":"13296_CR23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clcc.2016.08.008","volume":"16","author":"T Pinter","year":"2017","unstructured":"Pinter T, et al. A phase III, Randomized, Double-Blind, placebo-controlled trial of Pegfilgrastim in patients receiving first-line FOLFOX\/Bevacizumab or FOLFIRI\/Bevacizumab for locally advanced or metastatic colorectal Cancer: final results of the Pegfilgrastim and Anti-VEGF evaluation study (PAVES). Clin Colorectal Cancer. 2017;16:103\u201314. e103.","journal-title":"Clin Colorectal Cancer"},{"key":"13296_CR24","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1007\/s00520-017-3703-y","volume":"25","author":"GH Lyman","year":"2017","unstructured":"Lyman GH, et al. The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review. Support Care Cancer. 2017;25:2619\u201329.","journal-title":"Support Care Cancer"},{"key":"13296_CR25","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1007\/s00520-010-1020-9","volume":"19","author":"S Loibl","year":"2011","unstructured":"Loibl S, et al. Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33). Support Care Cancer. 2011;19:1789\u201395.","journal-title":"Support Care Cancer"},{"key":"13296_CR26","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1200\/JCO.2012.44.6229","volume":"31","author":"MJ Aarts","year":"2013","unstructured":"Aarts MJ, et al. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia. J Clin Oncol. 2013;31:4290\u20136.","journal-title":"J Clin Oncol"},{"key":"13296_CR27","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1200\/JCO.2012.48.3644","volume":"31","author":"MJ Aarts","year":"2013","unstructured":"Aarts MJ, et al. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia. J Clin Oncol. 2013;31:4283\u20139.","journal-title":"J Clin Oncol"},{"key":"13296_CR28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00520-015-2777-7","volume":"24","author":"IM Bondarenko","year":"2016","unstructured":"Bondarenko IM, et al. Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies. Support Care Cancer. 2016;24:267\u201373.","journal-title":"Support Care Cancer"},{"key":"13296_CR29","doi-asserted-by":"publisher","first-page":"714","DOI":"10.3892\/mco.2016.1062","volume":"5","author":"M Shirasawa","year":"2016","unstructured":"Shirasawa M, et al. Interstitial pneumonia following administration of pegfilgrastim during carboplatin and etoposide chemotherapy for small-cell lung cancer. Mol Clin Oncol. 2016;5:714\u20136.","journal-title":"Mol Clin Oncol"},{"key":"13296_CR30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/cup.12042","volume":"40","author":"M Llamas-Velasco","year":"2013","unstructured":"Llamas-Velasco M, et al. Sweet\u2019s syndrome with subcutaneous involvement associated with pegfilgrastim treatment: first reported case. J Cutan Pathol. 2013;40:46\u20139.","journal-title":"J Cutan Pathol"},{"key":"13296_CR31","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s40258-013-0011-7","volume":"11","author":"L Perrier","year":"2013","unstructured":"Perrier L, et al. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial. Appl Health Econ Health Policy. 2013;11:129\u201338.","journal-title":"Appl Health Econ Health Policy"},{"key":"13296_CR32","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/jjco\/hyy030","volume":"48","author":"O Miyake","year":"2018","unstructured":"Miyake O, et al. Costs associated with febrile neutropenia in Japanese patients with primary breast cancer: post-hoc analysis of a randomized clinical trial. Jpn J Clin Oncol. 2018;48:410\u20136.","journal-title":"Jpn J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13296-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-13296-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13296-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T16:06:56Z","timestamp":1734538016000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-13296-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["13296"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-13296-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"22 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board of Peking Union Medical College Hospital approved this study (No. JS1723). The registration number is NCT03793205 (<i>clinicaltrials.gov<\/i>, registered on January 4, 2019). All patients provided informed consent before participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for publication"}},{"value":"All the authors declare that they have no conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1512"}}